Hogan Lovells Achieves Victory for Eli Lilly in Patent Litigation
19 March 2012
LONDON, 19 March 2012 - Hogan Lovells has advised Eli Lilly in a patent litigation against failing generics company SAS Sandoz before the Court of Appeal of Paris, which confirmed a previous judgment which found that the French part of Eli Lilly's patent No. EP 0 577 303 (regarding a process for stereoselective glycosylation), shows inventive activity, is sufficiently disclosed and is consequently valid.
SAS Sandoz, which had already failed to make its case on first instance and had consequently been ordered to bear all of the counsels' costs of Eli Lilly, will therefore not be able to use the patented process, and is furthermore ordered to pay a record-high total of €504,000 in attorney's fees.
Eli Lilly was advised by Paris-based partner Dominique Ménard, working with senior associate Stanislas Roux-Vaillard and associate Loïc Lemercier.
Hogan Lovells was technically assisted by Thierry Caen, European Patent Attorney and partner at Cabinet Santarelli, and Léa-Marie Rougemont, Industrial Property Consultant.
About Hogan Lovells
Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses.
The word "partner" is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members.
For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com .
Where case studies are included, results achieved do not guarantee similar outcomes for other clients. Attorney Advertising.